Valeant Pharmaceuticals has appointed William Humphries as executive vice president (EVP), dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's executive committee, reporting directly to Joseph Papa, Valeant's chairman and chief executive officer (CEO).
Mr. Humphries has nearly 30 years of experience in the dermatology and specialty pharmaceuticals industry. He joins Valeant from Merz GmbH & Co. KGaA, where he most recently served as CEO of its North America business. Prior to Merz, he served as president of Stiefel, a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan, including vice president of the US skincare business.
Valeant has also announced several departures from the company. Anne Whitaker, EVP and company group chairman has decided to leave the company on January 13, 2017. Rob Rosiello will depart on December 31, 2016. Mr. Rosiello previously served as the Valeant chief financial officer (CFO) from July 2015 through August 2016 and has transitioned the role to the company’s new CFO, Paul Herendeen. Dr. Ari Kellen, EVP and company group chairman, will depart on December 31, 2016.
Source: Valeant Pharmaceuticals